Elicio Therapeutics, Inc. (ELTX)
Elicio Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: $12.00 - $14.00
Current IPO price range
| Market Cap | 180.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.90M |
| Shares Out | 13.88M |
| EPS (ttm) | -1.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
News
Elicio Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
About ELTX
Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. For therapies designed to engage the immune system to treat disease, it is critical to target activation at the unique location where adaptive immune responses are generated. Our proprietary Amphiphile, or AMP, platform delivers immunotherapeutics directly to the “brain center” of the immune system - the lymph nodes. We believe this site-specific delivery of disease-specific antigens, a... [Read more...]
| Industry Pharmaceutical Preparations | IPO Date Pending |
| CEO Robert Connelly | Employees 22 |
| Stock Exchange NASDAQ | Ticker Symbol ELTX |